Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

Completed

Conditions studied: Stroke, Systemic Embolism, VTEt and VTEp

In brief

The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated by the RM tools.

Key facts

Study ID

NCT02339818

Run by

Bristol-Myers Squibb

People needed

126

Starts

2015-08-01

Expected to finish

2017-02-01

Last updated by the study team

2017-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HCP must have been involved in the treatment of at least one patient with Eliquis for any approved indication
• Patients must have taken Eliquis for any approved indication

Where it is running

• Local Institution — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.